SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001214659-22-003978
Filing Date
2022-03-15
Accepted
2022-03-15 16:37:22
Documents
59
Period of Report
2022-01-31

Document Format Files

Seq Description Document Type Size
1 az3322010q.htm   iXBRL 10-Q 854937
2 EXHIBIT 31.1 ex31_1.htm EX-31.1 8282
3 EXHIBIT 31.2 ex31_2.htm EX-31.2 7975
4 EXHIBIT 32.1 ex32_1.htm EX-32.1 6796
  Complete submission text file 0001214659-22-003978.txt   4289588

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE alxneuro-20220131.xsd EX-101.SCH 44340
6 XBRL CALCULATION FILE alxneuro-20220131_cal.xml EX-101.CAL 41228
7 XBRL DEFINITION FILE alxneuro-20220131_def.xml EX-101.DEF 198641
8 XBRL LABEL FILE alxneuro-20220131_lab.xml EX-101.LAB 316185
9 XBRL PRESENTATION FILE alxneuro-20220131_pre.xml EX-101.PRE 261288
53 EXTRACTED XBRL INSTANCE DOCUMENT az3322010q_htm.xml XML 571118
Mailing Address 3802 SPECTRUM BLVD, SUITE C112C TAMPA FL 33612
Business Address 3802 SPECTRUM BLVD, SUITE C112C TAMPA FL 33612 844-722-6333
Alzamend Neuro, Inc. (Filer) CIK: 0001677077 (see all company filings)

IRS No.: 811822909 | State of Incorp.: DE | Fiscal Year End: 0430
Type: 10-Q | Act: 34 | File No.: 001-40483 | Film No.: 22741684
SIC: 2834 Pharmaceutical Preparations